Data Privacy Protection: Which Way Forward? (05/27/2020)
Faculty:
Maggie Hodgson, Director Publication Management, Oncology Lead, Merck
Rob Matheis, PhD, MA, President and CEO, ISMPP
Avishek Pal, MSc, ISMPP CMPP,™ Scientific Communications Director, Cell & Gene, Novartis Oncology
Sonia A. Schweers, PharmD, ISMPP CMPP™, Medical Capabilities / Medical Effectiveness, Global Publication Practices Lead, Bristol-Myers Squibb
Moderator:
Carolyn Hustad, PhD, Chair, Annual Program Committee; Associate Vice President, Global Medical and Scientific Publications, MRL Scientific Affairs, Merck
Webinar Overview:
The recommendations of the International Committee of Medical Journal Editors (ICMJE) are the industry standard for determining authorship. ICMJE criterion #1 is the basis for author selection as it refers to contributors to the research – prior to the initiation of the publication. Interpretation of ICMJE criterion #1 varies within and between companies, resulting in inconsistent author decisions and disputes.
This presentation will discuss industry-wide challenges in author selection. Representatives of the ISMPP Authorship Algorithm Taskforce will unveil recommendations to standardize the interpretation of ICMJE criterion #1 and discuss next steps for adoption.
At the end of this session, participants should be able to:
Maggie Hodgson, Director Publication Management, Oncology Lead, Merck
Rob Matheis, PhD, MA, President and CEO, ISMPP
Avishek Pal, MSc, ISMPP CMPP,™ Scientific Communications Director, Cell & Gene, Novartis Oncology
Sonia A. Schweers, PharmD, ISMPP CMPP™, Medical Capabilities / Medical Effectiveness, Global Publication Practices Lead, Bristol-Myers Squibb
Moderator:
Carolyn Hustad, PhD, Chair, Annual Program Committee; Associate Vice President, Global Medical and Scientific Publications, MRL Scientific Affairs, Merck
Webinar Overview:
The recommendations of the International Committee of Medical Journal Editors (ICMJE) are the industry standard for determining authorship. ICMJE criterion #1 is the basis for author selection as it refers to contributors to the research – prior to the initiation of the publication. Interpretation of ICMJE criterion #1 varies within and between companies, resulting in inconsistent author decisions and disputes.
This presentation will discuss industry-wide challenges in author selection. Representatives of the ISMPP Authorship Algorithm Taskforce will unveil recommendations to standardize the interpretation of ICMJE criterion #1 and discuss next steps for adoption.
At the end of this session, participants should be able to:
- Discuss challenges impacting author selection for company-sponsored research
- Review the mission, vision, goals and accomplishments of the ISMPP Authorship Algorithm Taskforce
- Discuss the interpretation of ICMJE criterion #1 to inform author selection
- Identify next steps in the implementation of the recommendations